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Recent Advances in Chronic Obstructive Pulmonary Disease (COPD)
Prof. Peter MA Calverley
School of Clinical Sciences, University of Liverpool, UK. Email: pmacal@liverpool.ac.uk
The last decade has seen major changes in our understanding of the clinical importance, causes and treatment of COPD. Systematic 
epidemiological studies, such as the Burden of Obstructive Lung Disease (BOLD) study, have shown that the prevalence of this disease 
is around 9% of adults and is much commoner in developing countries than expected. Persistent inflammation secondary to oxidative 
stress and corticosteroid resistance seem to drive both airway thickening, fibrosis and contribute to emphysema. Reliance on a fixed 
forced expired volume (FEV) 1/ forced vital capacity (FVC) ratio may lead to misdiagnosis in some circumstances while bronchodilator 
responsiveness is not a feature of stable COPD. COPD persists even after smoking cessation, but a long-acting inhaled bronchodilator, 
if combined with inhaled corticosteroids, reduces exacerbation numbers, improves health status and probably decreases the decline in 
lung function and the risk of dying from COPD. Systemic problems often accompany advanced COPD which increases the risk of lung 
cancer cardiovascular disease and osteoporosis irrespective of background treatment. Exacerbations often cluster in periods of disease 
instability and are driven by a range of viral and bacterial pathogens, persistent lower respiratory tract colonisation being particularly 
important. Respiratory failure can be managed more effectively with non-invasive ventilation (NIV), but preventing the development of 
severe disease is the major public health goal and will require earlier intervention in at risk populations if we are to move forward from 
simply managing advanced symptomatic COPD.
Asthma Management: The Guidelines–Practice Gap
Dr. Omar Al-Rawas
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. Email: orawas@squ.edu.om
Asthma is a major global public health problem. In recent years, a large number of national and international asthma management 
guidelines have been published and disseminated. However, there is evidence that health care providers have not widely adhered to 
these guidelines. This poor adherence to guidelines appears to be universal and span the spectrum of physicians in public and private 
practice as well as in teaching and tertiary referral hospitals. The problem is compounded by poor patient compliance. As a result of 
these factors, many asthma patients receive inadequate care and have poor asthma control. The available data indicate a need for further 
educational programmes directed at both physicians and patients to utilise better the available and effective therapies. Since guidelines 
can contribute to improved care only if they succeed in moving actual practice closer to the recommended norm, an expanded asthma 
management programme that provides feedback to physicians on their compliance with asthma guidelines and its impact on asthma 
control may help improve implementation of the guidelines and better asthma control. 
Management of Interstitial Lung Disease (ILD)
Prof. Athol Wells
Royal Brompton Hospital, London, UK. Email: a.walls@imperial.ac.uk
The primary conceptual problem in the management of ILD is the fact that there is a multiplicity of individual disorders, but only a 
handful of management strategies. The art of managing ILD is to classify patient presentations to fit with available treatment approaches. 
Therefore, ILD needs to be classed broadly as: a) self-limited inflammation; b) major inflammation with progression to fibrosis; c) 
stable fibrotic disease; d) insidiously progressive fibrosis (with stabilisation a realistic goal); and e) inexorably progressive fibrosis. This 
pragmatic classification can be achieved with knowledge of: 1) likely cause, if any; 2) CT/biopsy findings; 3) quantification of disease 
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severity, and 4) evaluation of disease behaviour with time. Based on this classification, management distinctions can be made between: 
a) observation; b) high dose therapy to reverse inflammation, followed by longer term low dose therapy to preserve gains; c) long-term 
low dose therapy from the outset with the realistic hope of preventing progression; d) long-term low dose therapy in the hope of slowing 
progression, and e) best palliative care in end-stage disease. The aim of this presentation is to demonstrate that with a minimum of 
readily obtainable information, it is possible to move from diagnostic uncertainty to confident pragmatic management in ILD, using 
terminology that is immediately understood by the patient, family and referring physician.
Primary and Secondary Prevention of Cardiovascular Disease
Prof. David Wood
National Heart and Lung Institute, Imperial College, London, UK. Email: d.wood@imperial.ac.uk
The WHO and Joint European Societies guidance on prevention of cardiovascular disease (CVD) in clinical practice recommends a 
common approach to lifestyle and risk factor intervention for patients with established atherosclerotic CVD and high risk persons in the 
population. This is based on the concept of total risk assessment and management first advocated in the Joint European recommendations 
on coronary prevention in 1994. The most recent report by the Joint European Societies, published in 2007, now addresses cardiovascular 
disease as a whole. The clinical priorities are: 1) patients with established atherosclerotic disease; 2) asymptomatic individuals who 
are at high risk of developing atherosclerotic disease because of a) multiple risk factors resulting in a ten year risk of  >5% now or, if 
extrapolated to age 60, for developing a fatal CVD event; b) markedly raised levels of single risk factors; c) diabetes mellitus, and 3) 
close relatives of patients with early onset atherosclerotic disease and asymptomatic individuals at particularly high risk. A new model 
for total risk estimation called SCORE (Systematic Coronary Risk Estimation), based on European populations, is recommended and 
can be adapted to correspond with national CVD mortality in any European country. The risk threshold for more intensive lifestyle 
intervention and, where appropriate, the use of drug therapies, is now defined as ≥5% fatal CVD risk over 10 years. Lifestyle, risk factor 
and therapeutic goals have been set for all priority patient groups. The most recent results from EUROASPIRE III show a continuing 
large gap between the professional standards set by guidelines and everyday clinical practice for both coronary patients and individuals 
at high risk of developing the disease in primary care. The EUROACTION demonstration project in preventive cardiology has stepped 
up to this professional challenge through a nurse coordinated multidisciplinary prevention programme which has set a new standard 
of preventive care for Europe.
Secondary Hypertension: Investigation and Management
Prof. Nicholas JY Woodhouse
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. Email: nickwood2@doctors.org.uk
Primary or essential hypertension (HTN) affects approximately 25% of the adult population worldwide and is a leading cause of mortality 
and morbidity. Frequently, two or more medications are required to achieve good blood pressure (BP) control and the financial costs to 
government are huge. Secondary hypertension, on the other hand, is potentially curable often without the need for lifelong medications. 
Patients should therefore be carefully screened to exclude treatable causes. In the literature, secondary disease is quoted as being 5% of 
the total hypertensive population, but the worldwide massive increase in obesity, together with more accurate data on the prevalence 
of primary hyperaldosteronism (PA) indicates that the total percentage is likely to be closer to 20%. The obesity epidemic has result 
in progressively more cases of the metabolic syndrome with its attendant dyslipidemia insulin resistance, type 2 diabetes (T2DM), 
obstructive sleep apnoea (OSA) and systemic HTN. This effect is compound by a parallel increase in alcohol consumption which on its 
own can produce persistent disease. In Oman, end stage renal disease (ESRD) requiring dialysis is estimated to increase by 10% annually 
again as a result of the increasing incidence of T2DM. At the present time, roughly 800 patients are undergoing dialysis and a similar 
number have had renal transplants. Endocrine causes of secondary HTN are rare, except in the case of primary aldosteronism which is 
found in 14% of the general UK hypertensive population and two-thirds of all hypertensive Omanis who have a positive family history 
of the disease. A careful family history and physical examination will give clues to the diagnosis in many patients. The remainder will 
require electrolyte, bone profile, hormonal studies and renal vascular imaging studies. In this brief review, we will illustrate these points 
with clinical examples and touch on new treatment options.
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Management of Stroke
Peter Langhorne
Prof. of Stroke Care, University of Glasgow, Scotland, UK. Email: P.Langhorne@clinmed.gla.ac.uk
The last decade has seen dramatic changes in our understanding of the management of stroke. This presentation will encompass recent 
developments in acute assessment and diagnosis, acute medical management, general (stroke unit) management, rehabilitation and 
secondary prevention. Acute assessment and diagnosis: One of the key changes in the public perception of stroke is the increased 
recognition of stroke as a medical emergency. This has encompassed developments to enhance the early recognition and diagnosis of 
acute stroke and transient ischaemic attack (TIA) patients together with the rapid triage for appropriate management. Acute medical 
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management: The main recent development has been the increased use of thrombolytic therapy in the form of recombinant tPA. 
Recent trials have supported an expansion of the time window and the challenge now is to make this available to all eligible patients. 
General (Stroke Unit) Management: Although the concept of stroke unit care is well established, many countries have recently made 
efforts to ensure that all stroke patients can access such care. The potential health gains from patients accessing appropriate stroke unit 
care are substantial. Rehabilitation: Substantial developments are taking place in our understanding of rehabilitation although research 
lags behind some other aspects of stroke management. Alternative models of rehabilitation (such as early supported discharge) are 
now becoming well established. Secondary prevention: This area of stroke management has been marked by two key themes: first, 
the recognition of the high risk of early recurrence after TIA or minor stroke; second, the establishment of a wide battery of effective 
secondary prevention measures including dual antiplatelet therapy, anticoagulation, early carotid endartorectomy, statin therapy and 
active blood pressure management. The presentation will include an assessment of the potential impact of the different strategies for 
managing strokes and the potential value at a public health level.
Management Issues for Women with Epilepsy
Dr Abdullah Al-Asmi
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. Email: aalasmi@gmail.com
Epilepsy is a chronic neurological disorder which presents with various syndromes and different aetiologies. It is estimated that more 
than one million women and girls in the USA are suffering from seizure disorders. There are a number of management issues related 
to epilepsy and women, especially in the childbearing age group. The menstrual cycle with its hormonal changes may affect seizure 
frequency. Catamenial epilepsy is defined as increased seizure related to the menstrual cycle, likely due to hormonal changes. Hormonal 
manipulation may significantly reduce such seizures.  Oral contraceptive pills (OCP) may interfere with antiepileptic drugs (AEDs) 
and vice versa.  Selection of the appropriate OCP for these women is essential. In addition, women should be counselled about a slight 
increase in the potential risk of unplanned pregnancy even though taking OCP. Certain AEDs, e.g. valproate, may cause irregular 
periods, weight gain and can lead to polycystic ovarian syndrome. Pregnancy can lead to increase in seizure frequency in women with 
epilepsy. This is due to multiple factors including hormonal factors, changes in the level of AEDs, etc.  Planning of pregnancy becomes 
very important with the aim to use minimum AEDs and as low a dosage as possible. The pregnant woman should be counselled about 
the potential teratogenic effects of the AEDs even though this is small. Over 90% of babies delivered by women with seizure disorders 
are healthy and normal. It is noted that many general physicians may advise the patient to stop AEDs during pregnancy fearing the 
teratogenic effect. This, unfortunately, may lead to increased seizure frequency during pregnancy and unwanted consequences for the 
mother and the foetus. Almost all AEDs have potential teratogenic side effects. Congenital anomalies are variable and include neural 
tube defect, and congenital heart diseases. These patients ideally should be followed as high risk pregnancy cases where regular obstetric 
ultrasounds and blood tests are done. The long term side effects of AEDs on the babies of these women is not well established, therefore 
it is important to develop and maintain a pregnancy registry at national and international levels. Delivery is a stressful and exhausting 
event which may precipitate seizures. The postnatal period may lead to increased seizure frequency due also to many factors including 
poor sleep, and hormonal changes. Also concerns will arise regarding lactation and potential side effects of AEDs on the neonate. In 
general, lactation is considered safe with special precaution among mothers who are taking benzodiazepines and phenobarbitol or 
primidone. There are many management issues physicians face when dealing with women who have epilepsy requiring the treating 
doctors to be well informed about this disease.
Viral Encephalitis
Dr Nick Beeching
Senior Lecturer (Clinical) in Infectious Diseases, Liverpool School of Tropical Medicine, Liverpool, UK. Email: nbeeching@blueyonder.co.uk
Encephalitis, or inflammation of the brain, has many causes and there is an overlap of clinical presentation with bacterial and viral 
meningitis and a wide variety of encephalopathies caused by metabolic and degenerative conditions, other infections, drugs and alcohol. 
Infectious causes include the herpes group of viruses, especially herpes simplex virus (HSV) and varicella zoster virus, enteroviruses, 
bacteria (especially Listeria), tuberculosis, and a wide range of geographically based viruses such as rabies, tick-borne encephalitis, 
Japanese encephalitis virus, Ross River virus and emerging problems such as Nipah virus and the spread of West Nile virus. Non-
infectious causes include immune mediated conditions, particularly acute disseminated encephalomyelitis (ADEM), paraneoplastic 
syndromes and voltage gated potassium channel limbic encephalitis. There is a rising incidence of encephalitis in immunosuppressed 
individuals, including viral causes e.g. cytomegalovirus (CMV), human herpes virus 6 (HHV6), Eppstein-Barr (EBV) virus infection, 
subacute encephalitis due to polyoma viruses JC/BK, and parasitic causes e.g. Toxoplasma gondii. The medical history should enquire 
about details of travel, animal exposure and occupation and leisure activities. Incidence rates are typically quoted as 5–10/100,000 per 
year, and are higher in the young and the elderly. In the UK, there are thought to be about 1.5 hospitalisations per 100,000 per year due to 
HSV encephalitis. The classical clinical description of a flu-like illness prodrome leading to confusion, headache, fever, seizures and focal 
neurological signs may be more subtle, and easily confused with neuropsychiatric problems. Common diagnostic and management 
errors include: attributing fever and confusion to urinary tract or respiratory infection; ignoring subtle mental changes described by 
relatives; missing a fluctuating fever if temperature is normal at presentation; failure to investigate and manage seizures, and failure to 
perform adequate neuroimaging and/or lumbar puncture. All patients require neuroimaging, often CT initially for features of raised 
intracranial pressure followed by MR scans which show more subtle changes, but both may be normal at presentation and require 
repeating. Lumbar puncture (LB) should be performed unless there are specific contraindications, although the cerebrospinal fluid 
(CSF) findings overlap with viral and bacterial meningitis and there may be a predominance of CSF neutrophils early in viral encephalitis. 
Increasingly sensitive polymerase chain reaction (PCR) techniques have largely replaced brain biopsy and antibody detection in viral 
diagnosis, especially for HSV, varicella zoster virus (VZV), CMV and enteroviruses. HIV testing should be part of the routine workup. 
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EEG is particularly useful for detection of recurrent subtle seizure activity. Management includes review and control of any underlying 
predisposing condition, aggressive management of seizures, detection and control of raised intracranial pressure and specific antiviral 
medication. Empirical antiviral therapy (aciclovir) should be started early, often with antibacterial agents, if there are uncertainties 
about diagnosis and there are diagnostic delays while waiting for imaging or for opportunity for safe LP. Aciclovir reduces mortality 
from HSV encephalitis from about 70% to about 20%, but the optimum duration remains unknown (most physicians give 14–21 days). 
There is reasonable evidence that it should be started within 48 hours. Steroids are frequently used but their role remains unproven, 
particularly in less severe disease. The use of other immunomodulatory agents, particularly interferons, in most forms of encephalitis 
remains anecdotal or unproven. Encephalitis has a poor outcome, and two thirds of survivors have neuropsychiatric sequelae and up to 
25% have epilepsy. Patients and their families require prolonged support, and the need for chronic care and changes in family dynamics 
represent a substantial long term burden on them and health services. Patient support groups have an important role in assisting this 
process. US guidelines have recently been published (Tunkel, et al. Clin Inf Dis 2008; 47:303) and should be read together with informal 
UK guidance (Solomon et al. Pract Neurol 2007; 7:288–305). Joint BIS/BAN guidelines are being finalised for consultation in the UK. 
Performance indicators for clinical audit include adequate use of neuroimaging (or documentation of reasons for omitting it), use of 
empirical aciclovir and /or antibacterial agents, and targeted use of specific antimicrobials for identified aetiologies. Optimum “door to 
needle” times for best treatment need to be defined, as does the proportion of patients that should be investigated with CSF PCR.
Diagnosis and Management of Neuroendocrine Tumours (NETs)
Dr. Omayma Elshafie
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos Universtiy, Muscat, Oman. Email: omayma0@hotmail.com
Neuoroendocrine (NE) cells are enterchromaffin cells (EC) occupying the epithelial lining of the digestive and respiratory tract and were 
discovered by Prof. Kulchitsky. The term amine precursor uptake and decarboxylation (APUD) was first coined by Prof. Anthony Pearse 
to describe their histochemical features. Normally, they are widely distributed in the gut, giving rise to the term the diffuse endocrine 
system of the gut. Their function includes modulation of peristaltic reflexes and water, electrolyte, mucous and hormone secretion 
(e.g. 5HT). Octreotide is a somatostatin analogue, which binds mainly to receptor 2 in the cell membrane of the EC. This result is 
inhibition of hormone production and cell proliferation. As a result labelled octreotide may be used to locate and treat NET. NETs of 
the gastrointestinal tract were thought to be rare and usually present with symptoms related to the actions of the peptide they secrete. 
70% of these carcinoid tumours are present in the digestive system while 30% are in the lung. The carcinoid syndrome only occurs when 
vasoactive hormones reach the systemic circulation. This invariably means that the tumour has metastasised to the liver. Hormones 
secreted by the primary tumour into the portal vein are metabolised by the liver and do not cause flushing. Tumours of the pancreas are 
only 3% of the total. Of these, 50% are insulinomas, 25% gastrinomas, 20% non-functional and 5% PPomas, VIPomas, glucagonomas and 
somatostatinomas. Pancreatic tumours may form part of the multiple endocrine neoplasia type 1 (MEN 1) syndrome and sometimes 
secrete a number of other hormones including ACTH, GHRH and PTHrP. Their diagnosis is often delayed and most present with 
metastatic disease. Earlier diagnosis can be improved by taking good history and confirmed by serum chromogranin A measurements, 
octreotide scanning  and immunohistochemistry. Advances in the treatment of NETS  with metastatic disease includes the use of:  1)
Sandostatin long acting octreotide (LAR); 2) Octreotide + RAD 001 (mTOR) Inhibitor); 3) Somatostatin receptor targeted radiotherapy. 
The incidence of NETs appears to be increasing. Early diagnosis is critical to improve survival, but the prognosis of patients with 
metatastatic disease has improved considerably with new treatment strategies.
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Chronic Viral Hepatitis B and C Infection
Prof. Humphrey Hodgson, Sheila Sherlock 
Chair of Medicine and Director, Centre for Hepatology, Royal Free Hospital; Senior Censor & Vice-President Education & Training, Royal College of Physicians of 
London, UK. Email: h.hodgson@madsch.ucl.ac.uk
Overview: Chronic viral Hepatitis B and C infections constitute a world health problem numerically far in excess of HIV disease. 
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) both predispose to cirrhosis, liver failure and liver cancer, but the rate of 
progression (infection to cirrhosis), though variable, is slow, and generally at least 10–20 years. Prevalence rates vary geographically 
depending on both genetic and more importantly environmental (e.g. transmission mode) factors. Current UK figures for each virus 
are ~0.5% of unselected populations so not dissimilar to published Omani results. However there are at-risk populations, which are 
different for each virus in the UK, for HBV: origin from high prevalence areas, intravenous drug abuse and promiscuity; for HCV: drug 
abuse, transfusions prior to 1990s. Importantly, HBV and its complications are preventable by immunisation, pursued as a policy in well 
over 100 nations.  An HCV vaccine is not yet available. Natural history and treatment of HBV: The response to HBV infection varies 
with age and immune status. Most infants become chronic carriers. Most adults have an episode of acute self-limited infection (which 
is often asymptomatic) but a small proportion (~5%) also becomes chronic carriers. Amongst the childhood-infected, there may be 
many years of ‘tolerance’ to the virus with high levels of viral DNA in the blood, but no liver damage. This is then typically followed by 
an immune attack on viral-infected liver cells (sero-conversion) associated with a change in immune markers in the blood (e-ag+ve to 
e-ab+ve) during which fibrosis and eventually cirrhosis may result. Treatment strategies vary. Paradoxically, the high viral DNA level (no 
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liver damage immunotolerant stage) is generally not treated until there is evidence of liver damage with elevated transaminase levels. 
Treatment options then include either immune activation (interferon therapy for 6–12 months), or direct antiviral drugs probably long 
term.  First generation antiviral drugs lead to high levels of viral resistance (i.e. lamivudine resistance in 40–60% of patients after 4 years); 
newer generation drugs after 3 years are showing much less resistance (0–2%).  With later stage disease, (after seroconversion), if there 
is active inflammation and high viral DNA levels, the antiviral drugs are the appropriate approach. In general, these strategies do not 
cure the disease but suppress the virus. The costs of long term therapy are high. Natural history and treatment of HCV: Most (>60%) 
of patients who contract HCV infection become long-term carriers. Anti-HCV antibodies persist in all who are infected, so chronic 
carriers need to be identified by detecting HCV-RNA in the blood by polymerase chain reaction (PCR) testing. Unlike HBV, successful 
treatment can cure the patient with chronic HCV, i.e. a sustained viral response (SVR). Treatment involves 6–12 months of pegylated 
interferon injections (weekly) in combination with daily ribavirin.  Different HCV subtypes (genotypes) respond differently. Genotype 1 
responds relatively poorly (40% SVR with 48 weeks therapy) whilst Genotype 3 does well (80% after 24 weeks or even shorter periods). 
Genotype 4 is intermediate. Fatigue, anaemia, depression, thrombocytopaenia and leucopaenia may all limit therapy. General measures 
in chronic viral liver disease: Liver decompensation requires treatment as it occurs, including consideration for liver transplantation. 
However in patients who are well with compensated cirrhosis, surveillance for hepatocellular cancer is worthwhile as, if detected early, 
surgical approaches or local ablation can enhance survival.
Bone as an Endocrine Organ
Prof. Graham Russell
The Botnar Research Centre, Oxford University Institute of Musculoskeletal Sciences, Oxford, UK. Email: graham.russell@ndos.ox.ac.uk
There have been remarkable recent advances in knowledge about skeletal biology and the changes that take place in disease. These are 
largely the result of discoveries in genetics and cell biology. Skeletal development is programmed by the sequential activation of specific 
genetic pathways, that culminate in the production of the adult skeleton which is light but strong. Systemic hormones, including the 
parathyroid hormone (PTH), vitamin D metabolites, and calcitonin, regulate blood calcium levels and contribute to the overall calcium 
economy of the body. Many other hormones have subtle but important effects on skeletal behaviour and its modelling and remodelling 
activity. In addition to understanding how osteoblasts form bone, and osteoclasts resorb bone, the important role of osteocytes as 
mechanosensors is receiving increasing attention. A novel and emerging concept is the notion that bone may itself function as an 
endocrine organ, not only locally but also systemically. At a local level, the integration of cellular differentiation and function within 
the microenvironment of bone is under the influence of a large number of cytokines and growth factors. There are several important 
recently discovered pathways that are involved in osteoblast regulation and osteoblast/osteoclast interactions and some of these are 
suitable for pharmacological intervention, including the wnt/LRP5 pathway, the ephrin system, and particularly the receptor activator of 
nuclear kappa beta (RANK) Ligand/RANK/osteoprotegerin (OPG) system. At a systemic level, there is evidence that products of bone 
cells may have distant endocrine effects. Indeed, osteocytes have their own repetoire of regulatory molecules, including FGF23, which 
is involved in phosphate metabolism, and sclerostin which is a powerful negative regulator of bone formation. Furthermore there is 
evidence that osteocalcin, secreted by osteoblasts, may act as a systemic metabolic regulator by controlling insulin secretion, and insulin 
sensitivity. There are also potential regulatory links between the hypothalamus, the gut, and adipose tissue involving leptins, serotonin, 
and adipokines. This new knowledge is offering novel opportunities for therapeutic interventions.
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Management of Chronic Kidney Disease
Dr. Dawood Al Riyami
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. Email: alriyamidawood@yahoo.com
All patients with renal disease (whether acute or chronic) should undergo an assessment of renal function by estimating the glomerular 
filtration rate (GFR). This measurement is used clinically to evaluate the degree of renal impairment. The kidney is able to adapt to 
damage by increasing the filtration rate in the remaining normal nephrons, a process called adaptive hyperfiltration. As a result, the 
patient with mild renal insufficiency often has a normal or near-normal serum creatinine concentration. The K/DOQI working group 
defined chronic kidney disease in adults as: evidence of structural or functional kidney abnormalities (abnormal urinalysis, imaging 
studies, or histology) that persist for at least three months, with or without a decreased GFR (as defined by a GFR of less than 60 mL/
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min per 1.73 m2). Chronic kidney disease (CKD) alone is an independent risk factor for cardiovascular disease. Among patients with 
CKD, the risk of death, particularly due to cardiovascular disease, is much higher than the risk of eventually requiring dialysis. The 
presentation covers the general management of CKD which involves: treatment of reversible causes of renal dysfunction; 2) preventing 
or slowing the progression of renal disease; 3) treatment of the complications of renal dysfunction, and 4) identification and adequate 
preparation of the patient in whom renal replacement therapy will be required.
Adult Stem Cell Transplantation in Autoimmune Disease
Prof. Alan Tyndall
on behalf of EULAR and EBMT. Email: alan.tyndall@fps-basel.ch
During 1995, informal discussions between members of the scientific committee of the European League Against Rheumatism 
(EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) concerning the potential of  haematopoietic 
stem cell transplantation (HSCT) for the treatment of severe autoimmune disease (AD) resulted in a consensus statement and the 
commencement of a small phase I/II trial. The mission statement of the working group was and remains “to show through prospective, 
randomised controlled trials (RCT) the place, if any, of HSCT in the treatment of severe AD.” A secondary aim is to increase the 
understanding of AD onset and persistence through mechanistic scientific side-studies. Twelve years later, over 1,000 patients in Europe 
have received an HSCT (mostly autologous) for treatment of a severe AD, with around one third having improved significantly. In 
some, a durable clinical and serological remission has been observed, including normalisation of tissue changes in scleroderma and 
loss of autoimmune memory in SLE. In others, the treatment resulted in death, treatment related mortality (TRM) overall being 11% 
in 2005. A recent analysis indicates a reduction in the TRM. Currently three EBMT sponsored RCTs are in progress or completed 
in Europe (scleroderma, multiple sclerosis and Crohn’s disease), the scleroderma trial (ASTIS) being part financially supported by 
EULAR. EULAR has also recently launched a stromal cell working group to develop recommendations for the use of mesenchymal 
stem cells (MSC) as therapeutic agents in rheumatic disorders exploiting their anti-inflammatory, immunomodulatory, tissue protective 
properties and apparent minimal acute toxicity. It is hoped that the preliminary positive results in acute graft versus host disease will 
translate to positive benefits for autoimmune diseases such as Crohn’s disease, lupus nephritis and vasculitis.
Genetic Basis of Common Diseases
Prof. Riad Bayoumi
Department of Biochemistry, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. Email: bayoumi@squ.edu.om
The recent advances in genomics and microarray technology at manageable cost, has enabled research groups, worldwide, to conduct 
successful genome-wide association studies (GWA) unravelling some aspects of the genetics of complex traits and common diseases, such 
as Type 2 diabetes, obesity, myocardial infarction, stroke, asthma, schizophrenia, bipolar disorders, Alzheimer’s disease, Crohn’s disease, 
autoimmune diseases and some cancers. The newly discovered genetic architecture of these diseases is helping in the understanding 
of pathophysiology and the development of novel approaches to prevention and therapeutic applications. However, most of the GWA 
studies have been designed to detect potential susceptibility loci and genes attributable to common simple nucleotide polymorphism 
(SNPs) which are limited by the very design of microarrays. In almost all diseases tested up to date, the variants discovered could only 
explain 10–15% of the inherited predisposition (heritability). The next big move to identify the probable source of missing heritability 
is in examination of low frequency rare variants and copy number variants that awaits the design of novel microarrays and low cost 
high-throughput sequencing.
Epidemiology of Viral Pandemics
Dr. Nick Beeching
Senior Lecturer (Clinical) in Infectious Diseases, Liverpool School of Tropical Medicine, Liverpool, UK. Email: nbeeching@blueyonder.co.uk
Historically, the epidemic and pandemic spread of infections such as measles, plague, cholera, smallpox and syphilis have had 
devastating effects in Europe and elsewhere. Endemic infections that have been controlled worldwide by public health interventions 
have the potential to re-emerge rapidly if such measures are relaxed or thwarted, a recent example being the international dissemination 
of polio after disruption of immunisation programmes. Many factors influence the development progress of a pandemic, including 
crowding, travel, close proximity to host animals or livestock, infectivity to contacts, and the availability, feasibility and effectiveness 
of control measures. This presentation contrasts recent international experience with severe acute respiratory syndrome (SARS), avian 
influenza and “swine-flu”, focusing on the effects on political and economic planning and outcomes, and the reality for public health 
practitioners and clinicians at a local level. Lessons learnt from these events need to be disseminated to inform policy for dealing with 
future pandemics, which are inevitable.
Sickle cell disease (SCD) - The Road Towards Prevention and Cure
Dr Salam Alkindi, Department of Haematology, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. 
Email: sskindi@yahoo.com
Sickle cell disease is prevalent in Oman with 5.7% of Omani people carrying the gene and about 0.2% affected; therefore, it is estimated 
that 120–150 babies born in Oman every year will become patients with SCD. Although SCD is traditionally regarded as a predominantly 
red cell disease, it is a complex disease demonstrating a model for red cell interactions with white cells and the endothelial cell lining. 
Recent work from our laboratory on acute chest syndrome (which is one of the major causes of death in this disease) and vaso-occlusive 
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crisis (VOC), the most frequent presentation of this disease, just demonstrated this. An alteration in the level of nitric oxide as well as 
a shift in lymphocytes and monocytes activations plays a role in both conditions. Similarly, the altered red cells (sickled cells) leading 
to perturbed platelets and haemostatic functions plays an important role in stroke development, added to the hereditary component of 
thrombophilia in this syndrome. These changes are promising an important opening for studies in the various therapeutic interventions 
that are available for this disease such as hydroxyurea, and more recently low molecular weight heparin, nicosan, and other agents that 
are undergoing testing.  Also light is seen at the end of the tunnel with good progress made in reduced intensity conditioning (RIC) bone 
marrow transplant for patients with SCD. This was seen in the recent experience in our Centre, allowing the sickled and normal cells to 
co-exist together, and the use of stem cells to help patients with avascular necrosis of the hips (AVN), a crippling complication seen in 
some of our patients. Thus SCD is a unique disease requiring a multi-faceted approach.
Lymphoma is Different Here
Dr. Ikram A Burney
Sultan Qaboos University Hospital, Muscat, Oman. Email:ikramburney@hotmail.com
Lymphoma is a heterogeneous group of neoplastic disorders. Knowledge about different types, sub-types, and aetiology is evolving 
continuously, and the incidence is on the rise. With the advent of immunophenotype and molecular markers, it has become apparent 
that there is a significant heterogeneity in disease presentation and clinical course in different parts of the world. Amongst non-
Hodgkin’s lymphoma (NHL) cases, T-cell immunotype is much more frequent in the Far East than in developed countries in the West. 
Indolent lymphoma of B-cell immunophenotype constitute around 20% of all cases, compared to around 40% in the West. Diffuse 
large B-cell Lymphoma (DLBCL) constitutes 60% of NHL in developing countries, compared to up to 30% in developed countries. 
Whereas 38% of patients with aggressive NHL present with high or high-intermediate risk features in the International Prognostic Index 
(IPI) in developed countries, around 60% present with such features in developing countries. Around 50% compared to 25% present 
with primary extra-nodal disease. Between 7% and 30% of the patients present with concomitant hepatitis B virus (HBV) infection in 
developing countries, compared to <5% in the developed countries, while the incidence of hepatitis C virus (HCV) co-infection is 5–15 
fold higher in the developing countries. A significantly higher proportion of patients present with aberrations of bcl-2 gene, mutant type 
of p53 protein, and a higher Ki-67 index. There are reports to suggest that patients with an aggressive type of NHL from developing 
countries are more likely to be immunosuppressed, and have concomitant co-morbidities, such as diabetes mellitus, which has an impact 
not only on the aetiogenesis, but also on long-term outcomes. Furthermore, there are important differences in the gene polymorphisms 
in various ethnic groups, resulting in differences in susceptibilities to develop lymphoma. Taken together, these observations suggest 
that there is hitherto an unmet need to study NHL in developing countries as a distinct entity.
Medical Education
Prof. Nigel Bax
University of Sheffield, UK. Email: n.d.s.bax@sheffield.ac.uk
Hippocrates recognised the need for experiential learning in medicine, Osler highlighted the personal qualities needed to become 
a good doctor, as well as the role of medical schools, and over 4,000 years ago Hammurabi made laws to enhance patient safety. The 
requirement of a scientific foundation to medical practice was emphasised by Flexner in 1910 and has resulted in a style of medical 
education that remains evident today. However, since these principles were espoused, the stakeholders in medical education have 
changed considerably. Patients, employers, regulatory bodies, governments and students themselves are understandably now central to 
educational matters and the autonomy of medical schools and of clinicians who teach both students and doctors has waned. Changing 
models of care have altered learning opportunities and large teaching hospitals in many parts of the world are becoming less ideal 
places for learning about general medicine than previously.  Increased financial and time pressures on doctors to deliver care do not 
always integrate with plans to produce the next generation of high quality medical practitioners. The learning of medical sciences by 
students and doctors has decreased, possibly consequent to their curricula becoming occupied by other topics. The role of doctors 
has been challenged, both in terms of their clinical skills and from a financial viewpoint, with cheaper alternatives now available. The 
distinctiveness and value of a doctor is being increasingly questioned. Thus, what are the defining qualities of a doctor, not just at present 
but what would we wish them to be in 20 years time? How should these qualities and abilities be acquired and assessed?  The principles 
determined by our forbears, namely clinical experience, appropriate personal and inter-personal qualities and the understanding and 
support of society, with all activities underpinned by scientific knowledge, remain central to medical education. We should still heed 
these tenets and help ensure that all stakeholders, as well as those learning and teaching in medicine, are responsive to them.
Treating Osteoarthritic Pain: What are the Options?
Dr. Ali S M Jawad
Rheumatology Department, Barts and the London NHS Trust, Whitechapel, London E1 1BB, UK. Email: ali.jawad@bartsandthelondon.nhs.uk.
Over the last 10 years, several guidelines have been published for the treatment of osteoarthritis (OA). In 2000, the American College of 
Rheumatology published its management guidelines for the management of patients with OA of the hips and the knees. The European 
guidelines (EULAR) followed and more recently the National Institute for Clinical Excellence (NICE) in the UK and the Osteoarthritis 
Research Society International (OARSI) guidelines were published in 2008. Based on a published systematic search of clinical guidelines 
and systematic reviews, twenty six interventions recommended for the treatment of knee pain in older adults in primary care have 
been identified. For example, the NICE guideline lists five interventions regarded as “core treatments” for osteoarthritis of the knee: 
paracetamol, patient education and information, exercises, weight loss (if the patient is overweight), and topical non-steroidal anti-
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inflammatory drugs (NSAIDs). The guideline lists another 14 interventions, ranging from those that are safe (such as alterations to 
footwear or local heat and cold), to those that also are potentially harmful (such as oral NSAIDs, opioids, and surgery). Evidence 
exists that interventions recommended as core treatment for knee pain in older adults are underused, in particular, exercise, weight 
loss and the provision of written information. There appeared to be early reliance on pharmacological treatments with underuse of 
nonpharmacological interventions in early treatment choices.
Pregnancy and Rheumatic Diseases
Dr. Samar Elemadi
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman. Email:ali.jawood@bartsandthelondon.nhs.uk
Systemic lupus erythematosus (SLE) occurs frequently in women of childbearing age. Although patients with SLE are as fertile as 
women in the general population, their pregnancies may be associated with complications. The prognosis for both mother and child is 
best when SLE has been quiescent for at least six months prior to the pregnancy, and the patient's underlying renal function is stable 
and normal or near normal. Thus, family planning is important. Maternal health and fetal development should be monitored frequently 
during pregnancy. If possible, delivery should occur in a controlled setting. In addition, women with SLE should be followed by an 
obstetrician knowledgeable in high-risk pregnancies.
Childhood Primary Angiitis of the Central Nervous System
Dr. Reem Abdawani
Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman. Email: reemabd@hotmail.com
Childhood primary angiitis of the central nervous system (cPACNS) is a rare and potentially devastating condition. It poses the clinician 
with significant diagnostic and therapeutic challenges. An overview of cPACNS will be discussed with special considerations pertinent 
to children.
Vascular Aspect of Behcet's disease
Dr. Juma Al-Kaabi
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman. Email:kaabi@squ.edu.om 
Behcet’s disease (BD) is a chronic multisystem inflammatory disease characterised by recurrent mouth and genital ulcerations, uveitis, 
skin lesions along with musculoskeletal, central nervous system, gastrointestinal and other systems manifestations. The disease is 
associated with morbidity, mainly due to the eye and central nervous system manifestations. Furthermore, the mortality rate of BD has 
been reported to be higher than the general population with an estimated rate of 4-10%. Most of this mortality is related to vascular 
thrombosis, which accounts for about 40% of overall causes of mortality in BD. The vascular involvement varies from 7.7 to 43% 
depending on the ethnicity. Pulmonary artery aneurysms are the one of most series complications of BD, as these may rupture with 
fatal consequences. The presentation highlights the spectrum of the vascular manifestations of BD (vasculo-Behcet), with reference to 
Omani populations.  
Fit for Purpose and Fit to Practise - Revalidation and Recertification in the UK
Dr. Ian Starke
Medical Director, Revalidation, Royal College of Physicians, London, UK. Email: Ian.Starke@uhl.nhs.uk
The maintenance and continuing development of the professional competence of trained doctors are key elements in ensuring that 
patients receive the highest standards of care. In the UK, these processes began to be formalised in the 1990s with the introduction of 
Continuing Medical Education and later Continuing Professional Development as formal processes, built largely on the recording of 
what most doctors were already doing. The General Medical Council (GMC) consulted on revalidation in 2000 and produced guidance 
for licensing and revalidation in 2003. Annual medical appraisal was first introduced in 2001 to support formal revalidation, which 
would start in 2005. This process was halted by a series of high profile criminal and medical negligence cases, in particular the activities 
of Dr Harold Shipman. An extended public inquiry, chaired by Justice Dame Janet Smith, led to a series of reports, the last of which 
appeared in 2005.  In her reports, Dame Janet criticised many aspects of the regulation of doctors, and in particular stated that the 
current processes of appraisal were “patchy and not fit for purpose”. The Chief Medical Officer (CMO) for England, Sir Liam Donaldson, 
chaired a further inquiry, which led to the publication of a Report in 2006 (Good Doctors, Safer Patients)  and to the government 
White Paper, “Trust, Assurance and Safety” in 2007.  This proposed processes for the formal revalidation of all health professionals, and 
included: 1) A change from the criminal to the civil standard of proof in medical fitness to practise cases; 2) The development by the 
GMC of a new framework for appraisal based on “Good Medical Practice”;  3) The separation of revalidation into the two elements of 
relicensure (for all doctors) and specialist recertification (for doctors on the Specialist and General Practice registers held by the GMC); 
4) The creation of GMC Affiliates who would represent the GMC at Regional or Strategic Health Authority level; 5) The creation of the 
role of Responsible Officer (RO) in every organisation that employs doctors – responsible for making a positive recommendation on 
revalidation to the GMC; 6) A clear statement of the role of the Medical Royal Colleges and Faculties and their specialist associations 
in making a positive recommendation on specialist recertification; 7) An expectation that the Colleges and Faculties, co-ordinated 
by the Academy of Medical Royal Colleges, would develop standards of specialist practice, and means of assessing specialists against 
those standards. In July 2008, a further report from a working party chaired by the CMO emphasised the importance of relicensure 
and specialist recertification forming “intertwined strands of a single process”, and the need to maintain the “predominantly formative” 
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nature of appraisal. The New Framework for Appraisal and Assessment developed by the GMC was to become a “core module” within 
every appraisal encounter. Although medical revalidation is mainly a Department of Health (DH) (England) initiative, there is a clear 
understanding that the processes in the devolved nations will be closely aligned with that in England, and national Revalidation Delivery 
Boards have been established in Scotland and Wales, working closely with the UK Revalidation Programme Board. Revalidation has 
three aims: 1) to confirm that licensed doctors practise in accordance with the GMC’s generic standards (relicensure); 2) for doctors 
on the GP register and specialist register to confirm that they meet the standards appropriate to their speciality or general practice 
(recertification); 3) To identify, for further investigation and remediation, poor practice where local practice is not robust enough to do 
this or does not exist. The Royal College of Physicians (RCP) position on revalidation is that the primary objective should be to ensure 
continuing high standards of professional practice and the continuing improvement of those standards over time. A model of how 
the various processes will fit together has been developed by the GMC and the Academy. The GMC’s Revised Framework divides the 
professional performance of doctors into four Domains, each of which has three Attributes. The actions, behaviours and skills expected 
of a well-performing doctor are stated as a total of some 67 “standards”. In common with others, the RCP has developed a Specialist 
Framework setting out the supporting information required to demonstrate that a physician is practising according to the 12 Attributes. 
A number of tools have been, and continue to be, developed by the RCP to support physicians in obtaining and recording relevant 
supporting information. These include multi-source feedback, a patient survey, an enhanced CPD system, personal “point-of-care” 
learning and quality improvement tools and a bedside teaching assessment. High standards for appraisers and for their training and 
support have also been developed. The Responsible Officer (RO) role has been defined by the DH; the ways and circumstances in which 
ROs will link with the College and its Regional representatives are to be defined. The College will have a key role in the quality assurance 
of the appraisal and revalidation processes taking place within NHS organisations. All those working with patients will require a licence 
to practice, and thus a Responsible Officer and regular annual appraisal. The next steps in the process include: 1) Ten “Pathfinder” 
or “Whole-system” pilots in 2010-11; 2) The introduction of “Early Adopter” pilots in 2011–12, the start of revalidation for those 
involved; 3) The development of appropriate electronic support tools and consideration of data protection and inter-operability between 
systems; 4) The development of appropriate training for appraisers and ROs; 5) Development of supportive remediation methodology; 
6) Development of quality assurance mechanisms, and 7) Consideration of so-called “orphan” groups of doctors.
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